子宫内膜异位症/子宫腺肌病患者与无此病患者在激素替代治疗-冻融胚胎移植周期后妊娠与未妊娠时的孕酮水平均无差异
在激素替代治疗-冻融胚胎移植(HRT-FET)周期中,纳入1784例患者,其中560例子宫内膜异位症、1224例无此病。达到活产者中,子宫内膜异位症组与无此病组移植日血清孕酮水平无显著差异(13.6 ± 4.3 ng/ml vs 13.2 ± 4.4 ng/ml,P = 0.302)。未妊娠者中两组孕酮水平亦无显著差异(P = 0.709)。
要点
- HRT-FET后达到活产者中,子宫内膜异位症组与无此病组移植日孕酮水平无显著差异(P = 0.302)。
- 深部浸润型子宫内膜异位症(n = 142)和子宫腺肌病(n = 100)亚组孕酮水平与无子宫内膜异位症患者相比均无显著差异。
- 未妊娠者中子宫内膜异位症组与无此病组移植日孕酮水平无显著差异(P = 0.709)。
核心结论
- 在HRT-FET周期中,诊断为子宫内膜异位症的患者在冻融囊胚移植日不需要更高的孕酮水平即可达到活产。
- 达到活产者中,子宫内膜异位症组与无此病组移植日血清孕酮水平无显著差异。
研究设计与样本
- 在大学附属生殖医学中心开展观察性队列研究,纳入2019年1月至2021年12月期间接受单个自体冻融囊胚移植、使用外源性雌二醇和微粒化阴道孕酮准备内膜的患者,每例仅纳入一次。
- 共纳入1784例患者,平均年龄35.1 ± 4.1岁;560例子宫内膜异位症,1224例无子宫内膜异位症。
- 子宫内膜异位症诊断基于已发表的影像学标准(经阴道超声/磁共振成像)和/或组织学确认。
- 移植日晨间由单一实验室检测血清孕酮水平;主要结局为达到活产的子宫内膜异位症患者与无此病患者的移植日孕酮水平。
- 根据深部浸润型子宫内膜异位症或子宫腺肌病的存在进行亚组分析。
主要发现
- 560例子宫内膜异位症患者中179/560(32.0%)达到活产,1224例无子宫内膜异位症患者中381/1224(31.2%)达到活产。
- 达到活产者中,子宫内膜异位症组与无此病组移植日平均孕酮水平分别为13.6 ± 4.3 ng/ml和13.2 ± 4.4 ng/ml,无显著差异(P = 0.302)。
- 深部浸润型子宫内膜异位症亚组(n = 142)和子宫腺肌病亚组(n = 100)的平均孕酮水平分别为13.1 ± 4.1 ng/ml和12.6 ± 3.7 ng/ml,与无子宫内膜异位症患者相比均无显著差异。
- 调整BMI、产次、不孕年限、吸烟和地理来源后,子宫内膜异位症(系数0.38;95%CI:-0.63至1.40;P = 0.457)和子宫腺肌病(系数0.97;95%CI:-0.24至2.19;P = 0.114)均与HRT-FET日孕酮水平无关。
- 未妊娠者中,子宫内膜异位症组与无此病组移植日平均孕酮水平无显著差异(P = 0.709)。
关键数值与推荐
- 达到活产者中,子宫内膜异位症组(n = 179)移植日平均孕酮13.6 ± 4.3 ng/ml vs 无此病组(n = 381)13.2 ± 4.4 ng/ml,P = 0.302。
- 深部浸润型子宫内膜异位症亚组(n = 142)平均孕酮13.1 ± 4.1 ng/ml,与无子宫内膜异位症患者相比无显著差异。
- 子宫腺肌病亚组(n = 100)平均孕酮12.6 ± 3.7 ng/ml,与无子宫内膜异位症患者相比无显著差异。
- 调整后子宫内膜异位症与孕酮水平的系数0.38(95%CI:-0.63至1.40;P = 0.457)。
- 调整后子宫腺肌病与孕酮水平的系数0.97(95%CI:-0.24至2.19;P = 0.114)。
临床怎么用
- 本研究显示,诊断为子宫内膜异位症的患者在HRT-FET周期中冻融囊胚移植日不需要更高的孕酮水平即可达到活产。
- 将结果外推至其他实验室或不同给药途径和/或剂量的孕酮仍需验证。
局限性
- 本研究的主要局限性与其观察性设计相关。
- 将结果外推至其他实验室或不同给药途径和/或剂量的孕酮也需要验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do women with endometriosis who achieve a live birth (LB) after HRT-frozen embryo transfer (HRT-FET) have different progesterone levels on the day of transfer compared to unaffected women? SUMMARY ANSWER: In women achieving a LB after HRT-FET, serum progesterone levels on the day of the transfer did not differ between patients with endometriosis and unaffected patients. WHAT IS KNOWN ALREADY: In HRT-FET, several studies have highlighted the correlation between serum progesterone levels at the time of FET and LB rates. In the pathophysiology of endometriosis, progesterone resistance is typically described in the eutopic endometrium. This has led to the hypothesis that women with endometriosis may require higher progesterone levels to achieve a LB, especially in HRT-FET cycles without a corpus luteum. STUDY DESIGN, SIZE, DURATION: We conducted an observational cohort study at the university-based reproductive medicine center of our institution, focusing on women who underwent a single autologous frozen blastocyst transfer after HRT using exogenous estradiol and micronized vaginal progesterone for endometrial preparation between January 2019 and December 2021. Women were included only once during the study period. Serum progesterone levels were measured on the morning of the FET by a single laboratory. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were divided into groups based on whether they had endometriosis or not and whether they achieved a LB. The diagnosis of endometriosis was based on published imaging criteria (transvaginal sonography/magnetic resonance imaging) and/or confirmed histology. The primary outcome was progesterone levels on the day of the HRT-FET leading to a LB in patients with endometriosis compared to unaffected women. Subgroup analyses were performed based on the presence of deep infiltrating endometriosis or adenomyosis. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 1784 patients were included. The mean age of the women was 35.1 ± 4.1 (SD) years. Five hundred and sixty women had endometriosis, while 1224 did not. About 179/560 (32.0%) with endometriosis and 381/1224 (31.2%) without endometriosis achieved a LB. Among women who achieved a LB after HRT-FET, there was no significant difference in the mean progesterone level on the day of the HRT-FET between those with endometriosis and those without (13.6 ± 4.3 ng/ml vs 13.2 ± 4.4 ng/ml, respectively; P = 0.302). In the subgroup of women with deep infiltrating endometriosis (n = 142) and adenomyosis (n = 100), the mean progesterone level was 13.1 ± 4.1 ng/ml and 12.6 ± 3.7 ng/ml, respectively, with no significant difference compared to endometriosis-free patients. After adjusting for BMI, parity, duration of infertility, tobacco use, and geographic origin, neither the presence of endometriosis (coefficient 0.38; 95% CI: -0.63 to 1.40; P = 0.457) nor the presence of adenomyosis (coefficient 0.97; 95% CI: -0.24 to 2.19; P = 0.114) was associated with the progesterone level on the day of HRT-FET. Among women who did not conceive, there was no significant difference in the mean progesterone level on the day of the HRT-FET between those with endometriosis and those without (P = 0.709). LIMITATIONS, REASONS FOR CAUTION: The primary limitation of our study is associated with its observational design. Extrapolating our results to other laboratories or different routes and/or dosages of administering progesterone also requires validation. WIDER IMPLICATIONS OF THE FINDINGS: This study shows that patients diagnosed with endometriosis do not require higher progesterone levels on the day of a frozen blastocyst transfer to achieve a LB in hormonal replacement therapy cycles. STUDY FUNDING/COMPETING INTEREST(S): None declared. TRIAL REGISTRATION NUMBER: N/A.
引用
- Bourdon M, Sorel M, Maignien C, et al. Progesterone levels do not differ between patients with or without endometriosis/adenomyosis both in those who conceive after hormone replacement therapy-frozen embryo transfer cycles and those who do not. Hum Reprod. 2024. PMID: 38850031. doi:10.1093/humrep/deae114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。